1. Neurological Complications in COVID-19 Patients: Can Analysis of Specific Antibodies and Viral RNA in Paired Cerebrospinal Fluid and Serum be Used for Accurate Diagnosis of SARS-CoV-2 Neuroinflammatory Disease? A Case Series.
- Author
-
Lauridsen, Karin Holst, Olsen, Kristine Boisen, Lund, Eva Løbner, Jensen, Tomas O, Pedersen, Thomas Ingemann, Harboe, Zitta Barrella, Antsupova, Valeria, Rasmussen, Lasse Dam, Röser, Dennis, Banner, Jytte, Franck, Kristina Træholt, and Vorobieva Solholm Jensen, Veronika
- Subjects
BLOOD serum analysis ,CEREBROSPINAL fluid examination ,BIOMARKERS ,DISEASE progression ,SARS-CoV-2 ,COVID-19 ,BIOPSY ,NEUROLOGICAL disorders ,CENTRAL nervous system viral diseases ,RESEARCH methodology ,AUTOPSY ,IMMUNOHISTOCHEMISTRY ,RETROSPECTIVE studies ,NEUROINFLAMMATION ,NEUROLOGIC manifestations of general diseases ,VIRAL antibodies - Abstract
Background: Neurological complications during and after SARS-CoV-2 infection have been frequently described. The detection of either SARS-CoV-2 RNA or specific antibodies against SARS-CoV-2 in cerebrospinal fluid in the context of concomitant neurological manifestations indicates neuroinfection. Methods and Results: This is a retrospective descriptive analysis of cerebrospinal fluids and serum samples from 2 hospitalized patients and autopsy findings from 2 patients who died at home. Samples were analysed by 3 independent enzyme-linked immunosorbent assays. Specific antibodies against SARS-CoV-2 were detected in cerebrospinal fluids and paired serum in all 4 cases. Levels of antibodies in cerebrospinal fluids were highest in samples from a deceased man with critical progression of COVID-19 and detectable SARS-CoV-2 viral RNA in cerebrospinal fluid, serum, 4 brain biopsies and 15 additional tissue samples, though immunohistochemical staining for SARS-CoV-2 in brain tissue did not detect the virus. Conclusion: Detection of SARS-CoV-2 antibodies in paired serum and cerebrospinal fluid may support the presence of SARS-CoV-2 neuroinflammatory disease in patients with COVID-19 and neurological manifestations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF